HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia: a randomized, double-blind, multicenter phase III trial.

AbstractBACKGROUND:
Flexibility in the recommended dosing time for a statin may improve patient compliance.
OBJECTIVE:
This study was designed to compare the efficacy and tolerability of morning and evening doses of controlled-release simvastatin in Korean adults with dyslipidemia. It was carried out as a requirement to obtain authorization from the Korean regulatory agency to market the product.
METHODS:
In this prospective, randomized, double-blind, multicenter, placebo-controlled Phase III study, we randomly assigned 132 patients with hypercholesterolemia to a morning-dose group or an evening-dose group. Patients in the morning-dose group received 20 mg controlled-release simvastatin in the morning and a placebo in the evening, and those in the evening-dose group received a placebo in the morning and 20 mg controlled-release simvastatin in the evening.
RESULTS:
After 8 weeks of the treatment, the difference in the mean change of LDL-C between the morning-dose and evening-dose groups was -2.78% (95% confidence interval, -7.65 to 2.10). The changes in total cholesterol, triglycerides, HDL-C, apolipoprotein A1, apolipoprotein B, and lipoprotein (a) after treatment did not differ between groups. Also, the achievement rates of the target LDL-C goal suggested by the dyslipidemia treatment guideline of the Korean Society of Lipidology and Atherosclerosis were not different. No serious adverse event was observed in either group. Mild and moderate adverse events were observed similarly in both groups.
CONCLUSIONS:
Although controlled-release simvastatin significantly reduces LDL-C levels with good tolerability in Korean adults with dyslipidemia, the time of administration does not affect its efficacy.
AuthorsSang-Hyun Kim, Min-Kyung Kim, Hong-Seok Seo, Min-Soo Hyun, Kyoo-Rok Han, Seong-Wook Cho, Young-Kwon Kim, Seong Hoon Park
JournalClinical therapeutics (Clin Ther) Vol. 35 Issue 9 Pg. 1350-60.e1 (Sep 2013) ISSN: 1879-114X [Electronic] United States
PMID23998970 (Publication Type: Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© 2013 Elsevier HS Journals, Inc. All rights reserved.
Chemical References
  • Anticholesteremic Agents
  • Cholesterol, LDL
  • Delayed-Action Preparations
  • Tablets
  • Triglycerides
  • Simvastatin
Topics
  • Aged
  • Anticholesteremic Agents (administration & dosage, adverse effects, therapeutic use)
  • Cholesterol, LDL (blood)
  • Delayed-Action Preparations
  • Double-Blind Method
  • Drug Administration Schedule
  • Drug Chronotherapy
  • Female
  • Humans
  • Hypercholesterolemia (drug therapy)
  • Male
  • Middle Aged
  • Prospective Studies
  • Simvastatin (administration & dosage, adverse effects, therapeutic use)
  • Tablets
  • Triglycerides (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: